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Abstract
Cancer is a multifaceted disease that results from dysregulated normal cellular signaling networks
caused by genetic, genomic and epigenetic alterations at cell or tissue levels. Uncovering the
underlying protein signaling network changes, including cell cycle gene networks in cancer, aids in
understanding the molecular mechanism of carcinogenesis and identifies the characteristic signaling
network signatures unique for different cancers and specific cancer subtypes. The identified
signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past
several decades, the available technology to study signaling networks has significantly evolved to
include such platforms as genomic microarray (expression array, SNP array, CGH array, etc.) and
proteomic analysis, which globally assesses genetic, epigenetic, and proteomic alterations in cancer.
In this review, we compared Pathway Array analysis with other proteomic approaches in analyzing
protein network involved in cancer and its utility serving as cancer biomarkers in diagnosis,
prognosis and therapeutic target identification. With the advent of bioinformatics, constructing
high complexity signaling networks is possible. As the use of signaling network-based cancer
diagnosis, prognosis and treatment is anticipated in the near future, medical and scientific
communities should be prepared to apply these techniques to further enhance personalized
medicine.
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Introduction
Cancer Signaling Network
Cancer is a complex disease that results from complex sig-
naling network pathway alterations that control cell
behaviors, such as proliferation and apoptosis. The com-
plexity of signaling network is multidimensional given
the exceedingly high number of components (i.e. nodes
and hubs), multiple connections (i.e. edges) between
pathways (i.e. cross-talk) and many feedback loops (i.e.
redundancy and compensation) [1]. Furthermore, the
components in each signaling network operate at differ-
ent spatial and temporal scales with continuous, dynamic
changes in response to cell-cell and cell-stromal interac-
tions. This complex, dynamic signaling network collec-
tively affects cell function and behaviors with the
possibility of sub-network (or module) affecting different
function or behavior. Therefore, this multidimensional
complexity poses a great challenge in network biology
research.
Understanding signaling networks involved in carcino-
genesis significantly advances our knowledge of cancer
initiation and progression, including metastasis. Signal-
ing network alterations accumulate at each stage of car-
cinogenesis that results from genetic, epigenetic and
environmental changes and is viewed as a multi-step
model of carcinogenesis [2]. Furthermore, the specific sig-
naling networks that reflect the hallmarks of cancer have
been demonstrated and include the ability to mimic nor-
mal growth signaling, insensitivity to antigrowth signals,
ability to evade apoptosis, limitless replicative potential,
sustained angiogenesis, and tissue invasion and metasta-
sis [1,3].
Signaling network research is also important in diagnosis,
biomarkers, cancer progression, drug development and
treatment strategies. Recently, several studies have dem-
onstrated the feasibility of cancer signaling network-based
approaches for cancer diagnosis, prognosis and therapy
[4]. In this paper, we will review the latest advancements
and current progress in cancer signaling network research.
Genomic Based Approaches For Signaling Network
The ability to collect data from a large number of genes in
the same sample, including gene expression and DNA
alterations, opens the possibility of obtaining network-
level data. Currently, the signaling network information is
typically derived from genomic profiling studies includ-
ing gene expression, single nucleotide polymorphism
(SNP), copy number variations (CNV) and DNA methyl-
ation (see Additional file 1) [5-12]. A limitation of
genomic profiling studies is that mRNA levels and DNA
alterations may not accurately reflect the corresponding
protein levels and fail to reveal changes in posttranscrip-
tional protein modulation (e.g., phosphorylation,
acetylation, methylation, ubiquitination, etc.) or protein
degradation rates [13]. More importantly, the signaling
network constructed using these approaches does not
reflect the dynamic signal flow in a spatial relationship.
On the other hand, the genomic changes (mRNA level,
SNP, CNV, methylation) ultimately affect protein expres-
sion, activation and inactivation, which, in turn, controls
cellular behavior. Therefore, the use of a proteomics
approach that can add protein-protein and protein-DNA
information, which more accurately reflects the signal
flow and dynamic change in the signaling network and
could be a valuable addition to genomic profiling studies.
Challenges of Protein-Based Approaches
The major challenge of proteomic research is the limited
assay sensitivity of analyzing cell proteins. Although each
mammalian cell contains approximately 30,000 genes,
the proteins coded by these genes can be as many as
200,000 to 300,000 due to alternative splicing. Further-
more, the proteins involved in cellular homeostasis,
metabolism and structure are abundant and are present
10,000 to 100,000 fold greater than proteins involved in
signaling networks in an individual cell. Therefore, detec-
tion and quantification of these cell signaling proteins
poses a great challenge. Two dimensional gel electro-
phoresis (2D) or liquid chromatograph (LC) in combina-
tion with mass spectrometry (MS) is a widely used
technology to identify proteins. An important advantage
of these sensitive techniques is the ability to identify
unknown proteins in a complex sample. However, costly
instrumentation is typically required and often insuffi-
cient to detect proteins that are in low abundance.
On the other hand, antibody detection offers great sensi-
tivity and specificity to detect known proteins in a sample.
However, multiplex array, i.e. protein arrays, to identify
proteins with antibodies also has limitations. For exam-
ple, capture molecules are proteins themselves and tend
to denature with changes in pH or temperature. Further-
more, antigen-antibody interactions are determined by
complex associations between epitope sites on the target
protein and the antigen-binding site on the antibody,
which are both influenced by external conditions. Anti-
bodies must exhibit strong affinities and specificity for
each respective substrate, particularly when investigating
the activated state of specific proteins, such as phosphor-
ylation, glycosylation or proteolytic cleavage. Subse-
quently, activation-specific antibodies, routinely used in
Western blots, may not be suitable in an array format, as
the phosphorylation-specific site may be imbedded
within the interior aspect of protein and inaccessible to
the antibody.
Quantifying protein concentration represents another
problem when analyzing hundreds of antibody-antigenCell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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interactions in a single array as each antibody-antigen pair
possesses an independent affinity constant. However, the
variation in protein concentrations in cells may be as high
as 6 folds. Thus, detection methods must be developed to
quantify protein concentrations over many orders of mag-
nitude. The detection of antigen-antibody pairs is rou-
tinely performed by either sandwich assays in which two
complementary antibodies to different sites of the protein
are used, or by detecting a label on the protein itself. Con-
jugation of proteins may disturb the native folding struc-
ture of proteins and thus may destroy the antibody-
antigen interaction, yielding false negatives.
Proteomics-Based Techniques for Cancer Signaling 
Network Research
Although protein-based techniques such as 2D gel, MS
and antibody-antigen assays have long been available, the
application in clinical research is limited (see above).
However, during the past decade, the technologies have
significantly improved and have rapidly transitioned to
the clinical laboratories. The techniques can be catego-
rized into two groups: MS-based and antibody-based tech-
nologies (see Additional file 2). This section discusses the
most commonly used protein detection techniques as
well as computational methods for data analysis and net-
work simulation.
Detection of unknown proteins by two dimensional gel 
electrophoresis and mass spectrometry
Two Dimensional (2D) gel electrophoresis is a technique
in which proteins in a complex protein mixture (such as
cell and tissue samples) are separated according to two
dimensions (Figure 1). 2D gel electrophoresis is used pri-
marily to analyze and identify existing proteins in a given
sample. 2D gel electrophoresis is a mainstream technol-
ogy used for proteomic investigations. In this method,
proteins are separated in the first dimension according to
charge by isoelectric focusing, followed by separation in
the second dimension according to molecular weight,
using polyacrylamide gel electrophoresis. Then, the gels
are stained to visualize separated protein spots using a
Coomassie, silver or fluorescent stain. Using this
approach, up to several thousand protein spots can be
separated and visualized in a single experiment. Gels of
different samples are compared and analyzed using com-
puter software. Then, differentially expressed protein
Schematic representation of protein identification by gel electrophoresis and mass spectrometry (MS) Figure 1
Schematic representation of protein identification by gel electrophoresis and mass spectrometry (MS). The 
proteins in a sample are separated using a 2 dimensional gel electrophoresis. Each individual protein is extracted from gel and 
identified by MS.
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spots are excised, digested into fragments and identified
using MS.
Recently, a modified 2D protein electrophoresis tech-
nique, Differential in Gel Electrophoresis (DIGE), was
developed to monitor differences in the proteomic profile
of two separate samples. In this method, 2-3 paired sam-
ples can be run on the same 2D gel after labeling with
each cyanine dyes (Cy2, Cy3 and Cy5). After completing
the 2D electrophoresis, the proteins in each sample are
detected by a phosphorimager with different fluorescent
channels. The different fluorescent images of the same gel
are superimposed to identify and quantify differentially
expressed proteins. This approach reduces experimental
variation, increases quantification accuracy and improves
the sensitivity of the technique. The differentially
expressed protein spots are then excised from the gel,
digested to fragments and identified by MS.
Peptide fragments derived from 2D gel electrophoresis (as
well as liquid chromatography) is a precursor to mass
spectrometry (MS), a process that identifies the ratio of
elemental and isotopic components in a given sample
(Figure 1). The principle of MS is that the molecules or
proteins in the sample are ionized from the solid to gase-
ous phase via an ion source. The ions are then separated
from each other based on their mass-to-charge (m/z)
ratios in the mass analyzer. Finally, the ions are detected,
the abundance of each ion is calculated and the structure
of the protein is determined by comparing the database
against a known protein sequence database [14]. In the
past decade, MS has significantly advanced, including
improved ionization (matrix assisted laser desorption/
ionization (MALDI), electrospray ionization (ESI), sur-
face-enhanced laser desorption ionization (SELDI)) and
more sensitive mass analyzers (time-of-flight (TOF), ion
trap, and quadrupole). The combination of these systems
offers a higher sensitivity (femtomole or picogram), reso-
lution and mass accuracy. In the future, high through-put
identification of proteins, broad dynamic range of quanti-
fication (104 to 105) and characterization of post-transla-
tional protein modifications will be possible.
Detection of known proteins with protein microarray
Protein microarray technology is a powerful emerging
analytical strategy for interrogating the proteomes of tis-
sues and cells. As a high-throughput screening platform,
protein microarray permits rapid quantitative identifica-
tion of cancer biomarkers associated with oncogenesis
and disease progression. Protein microarray can accelerate
the current understanding of cellular differentiation,
transformation, angiogenesis, tumorigenesis, and metas-
tasis. This new technology has the ability to 1) quickly elu-
cidate alterations in protein expression levels, 2) detect
post-translational modification and mRNA processing
events, and 3) dissect molecular networks associated with
drug administration or exposure to environmental factors
(for example, toxins, infectious agents, or radiation). With
the advent of protein microarrays, global profiling cancer
signaling network diagnosis and prognosis as well as per-
sonalized therapy becomes possible. There are several dif-
ferent types of protein arrays, including reverse phase
protein array, antibody array, etc [15] that may be per-
formed on several supporting platforms, including glass
slides, membranes, and beads.
Protein arrays are typically high-density arrays (>1,000
elements/array) used to identify novel proteins or pro-
tein/protein interactions (Figure 2A). The protein library
arrayed on the slide can be derived from many possible
sources including expression libraries and may contain
known as well as unknown elements. Protein arrays can
be used to analyze patient samples, including serum and
bodily fluids. To detect proteins that are bound to the
array, the antibodies must be labeled directly with a fluor-
ophore or a hapten. Alternatively, in some applications,
antibodies can be used to detect binding events [16,17].
Reverse phase protein arrays are used to profile dozens
or hundreds of samples (research or clinical) for the pres-
ence of a small number of antigens (Figure 2A). Cell
lysates, material from laser capture microdissection, or
serum samples are arrayed. This creates an array of
"unknowns" that can be probed with a small number of
antibodies. Visualization can be performed with a detec-
tion antibody linked to a fluorophore or color detection
reagent [18].
Antibody arrays and Microspot ELISA are used for quan-
titative profiling of protein expression in cells and clinical
samples (Figure 2B). Typically these arrays are low-density
(9-100 elements/array). However, the density of the anti-
body array is expected to increase and will continue to
expand due to the availability of a large number of high
affinity antibodies. In these arrays, known antibodies are
arrayed and used to capture antigens from unknown sam-
ples. To detect an antigen that is bound to the array, the
antigen is labeled directly with a fluorophore or a second
binder/antibody [19]. The latter option creates a sandwich
assay similar to a traditional ELISA, but in a microspot for-
mat. Thus, the term "microspot ELISA" is used.
Bead-based array is a potentially powerful complement
to planar arrays. The Luminex bead array system is
increasingly used in protein profiling applications (Figure
2C) [20]. The system uses multiple, different fluorescent
beads that are spectrally distinguishable and coated with
a different capture antibody. The beads are incubated with
a sample to allow protein binding to the capture antibod-
ies. The mixture is incubated with a mixture of detectionCell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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antibodies, each corresponding to one of the capture anti-
bodies. The detection antibodies are tagged to allow fluo-
rescent detection. The beads are passed through a flow
cytometer and each bead is probed by two lasers: one to
determine the identity of the bead based on the bead's
color and another to read the amount of detection anti-
body on the bead.
Pathway Array is an innovative, powerful tool to analyze
the expressed proteins with excellent sensitivity and spe-
cificity. This is an immunoblot-based assay and was
recently developed and validated in the authors' labora-
tory [21]. It allows for global screening of changes in pro-
tein expression and post-translational modification (i.e.
phosphorylation). The focus of the Pathway Array is to
determine the signaling network that controls cancer
development (initiation, promotion, progression and
metastasis). The proteins selected for study in the array are
highly expressed in cancer cells and are functionally
linked to angiogenesis, apoptosis, cell cycle regulation,
DNA repair, migration, proliferation, signaling, stem cell
association and transcription activity (see Additional file
3).
The Pathway Array system consists of three integrated
components (Figure 3): 1) One or two dimensional gel
electrophoresis/multiplex protein immunoblot or bead
array; 2) Image acquisition and data analysis; and 3)
Computational analysis to integrate the results with
known protein-protein, cell signaling and gene regulation
Antibody-based detection of sample proteins: A) Protein arrays or reverse phase protein arrays Figure 2
Antibody-based detection of sample proteins: A) Protein arrays or reverse phase protein arrays. Proteins are 
spotted on a support (i.e. glass slide). The primary antibody binds specifically to its protein. The secondary antibody conjugated 
with HRP (or fluorescence) then bind to the primary antibodies. The substrate is cleaved by HRP to develop detectable color. 
B) Antibody arrays. Antibodies are spotted on a glass slide and the proteins in the sample are captured on to the glass slide. 
Another antibody which binds to a different epitope of the protein is used to detect the protein. C) Bead-based array (Luminex 
platform). The Luminex bead is coated with the capture antibody which binds to the protein in the sample. Another antibody 
which binds to a different epitope is labeled with fluorescence for the detection. Red laser detects bead and green laser detects 
the antibody.
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cancer biology pathways. Our system measures relative
protein levels among different cell lines and tissues. More
importantly, the Pathway Array system can assist in iden-
tifying global functional changes in the complex signaling
network that drives cellular behavior.
The Pathway Array (1D gel/immunoblot) can assay sev-
eral thousands of proteins and phosphoproteins in each
sample, depending on the availability of high affinity
antibodies (see Additional file 3). Total proteins are
extracted from each fresh frozen tissue sample or cell lines
Flow chart of Pathway Array analysis Figure 3
Flow chart of Pathway Array analysis. The proteins from tumor and surrounding normal tissues are extracted and sepa-
rated by 2 dimensional gel electrophoresis (2D GE), 1 dimensional gel electrophoresis (1 DE) or Luminex beads. The presence 
of specific proteins is detected by mass spectrometry (MS), immunoblot or flow cytometry. Various computer programs are 
used for data analysis, clustering and network simulation.
Network simulation
Protein clustering
2D GE/MS 1 DE/Immunoblot Bead array/
flowmetry
Protein separation and detection
Computer analysis
p27
EGFR
cdk6Cell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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and separated using SDS-PAGE. The proteins are then
transferred to a nitrocellulose membrane and blotted
using a Western blotting manifold that isolates 20 chan-
nels across the membrane. Each channel includes 4 anti-
bodies (a total of 80 antibodies) for immunoblot and the
proteins specific to the antibody can be detected using a
chemiluminescent method (Figure 4). The images can be
acquired using the ChemiDoc XRS System (Bio-Rad) and
the correct band for each protein/phosphoprotein can be
determined by molecular weight. The volume of each
band can be recorded. The bound antibodies on the mem-
brane can then be stripped off and blotted with another
set of antibodies. This process can be repeated several
times so that up to 300-400 antibodies can be blotted
using the same membrane.
Pathway Array assay has several important features. The
coverage  of signaling network-related proteins is high
with at least one representative protein (typically 2-3)
included for each pathway (see Additional file 3). The
selection of antibodies was based on previously described
functionality in the literature, the Human Protein Atlas
http://www.proteinatlas.org/ and commercial availabil-
ity. It is estimated that approximately 500 genes code for
kinases, 1,500 genes code for transcription factors, 400
genes code for G-protein-coupled receptors and 1,200
genes code for candidate cancer biomarkers [22]. Cur-
rently, approximately 6,000 antibodies are commercially
available, which accounts for nearly 25% of all 21,528
predicted human genes [23].
We have validated the sensitivity and specificity of nearly
300 antibodies using different cell lines and human tis-
sues by Pathway Array with an average success rate of 50-
70%. The sensitivity (or limit of detection) of the assay is
about 1 ng for each band by a chemiluminescent detec-
tion method (more sensitive compared to conventional
Western Blot). The sensitivity can be further improved to
Representative immunoblots of benign (A) and malignant (B) tissues Figure 4
Representative immunoblots of benign (A) and malignant (B) tissues. The proteins from benign and malignant tissues 
were extracted and separated by SDS-PAGE. The proteins were then transferred to a nitrocellular membrane and placed in a 
manifold which separate the membrane into 20 channels. Each channel was blotted with 2-4 primary antibodies. The secondary 
antibody was detected by chemiluminescence. The positive signal as well as correct location ensures the correct identification 
of the proteins.
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0.1 ng with a fluorescent label (Cy3 and Cy5) and phos-
phorimager (Typhoon Trio Imager, GE Healthcare). The
specificity and accuracy of the Pathway Array in identify-
ing the correct proteins and phosphoproteins is better
than the conventional protein arrays and reverse phase
arrays since the correct identification of the protein is
based on its molecular weight with a reference to size
markers (Figure 4) (Note: false signal for the protein array
can be as high as 60%). Over 80-90% of the proteins iden-
tified by pathway array can be confirmed by conventional
Western blot. The reproducibility is also improved with
the inter- and intra-run variations: CV = 25% and 35%,
respectively, and a R2 = 0.933 between runs (Figure 5). The
average dynamic range of the assay (using chemilumines-
cence) is between 10 and 104 and is very sensitive in
detecting differences in protein expression (~2 fold
change between two samples). The assay is resistant to
interference from high abundance proteins (i.e. structural
and metabolic proteins which are 10,000~100,000 fold
higher than signal transduction proteins) due to the spe-
cificity of the antibody and the efficient gel separation.
Because of the above features, a higher discovery rate of
differentially expressed proteins and phosphoproteins
(20-40% of the proteins tested) was observed as com-
pared to other gene expression and proteomic-based
approaches (2-6% of the mRNA expression array or 2D/
MS). For example, we studied 39 pairs of non-small cell
lung cancer and surrounding normal tissues to identify
differentially expressed proteins using Pathway Array.
Among 108 proteins and phosphoproteins tested, 59 were
detected and 21 were differentially expressed with p <
0.05 as determined by SAM analysis. The detection rate
was 55% and the rate of discovering differentially
expressed proteins was 20%. The higher detection and dis-
covery rates of the Pathway Array are due to the inclusion
of antibodies that are highly relevant in carcinogenesis.
Computational Methods For Proteomic Array Data 
Analysis
Currently, a bioinformatic method specifically designed
for high density protein expression array analysis is una-
vailable. However, some statistical tools developed for
genomic microarray can be used for protein arrays. Exam-
ples of statistical tools that can be used for protein arrays
are listed below.
BRB-Array Tools is an integrated software package for the
analysis of genomic microarray data http://
linus.nci.nih.gov/BRB-ArrayTools.html. BRB-Array Tools
is an add-on to Excel and provides an user friendly plat-
form to perform ANOVA functions, cluster genes and
samples, functional and predictive sample classifications,
and data visualization tools [24]. The package is very port-
able and has unrestricted use with any particular array
platform, scanner, image analysis software or database.
BRB-Array Tools identifies differentially expressed genes
across groups (also referred to as "Class Comparison")
using reliable statistical methods designed to better man-
age the false discovery rate (FDR). It also constructs and
evaluates multivariate predictors for classifying unknown
samples into groups based on gene expression profiles
(also referred to as "Class Prediction"). For protein expres-
sion array analysis, the data set of protein expression sig-
nal intensities can be imported to BRB-ArrayTools in an
Excel format. The computations are performed by sophis-
ticated statistical tools external to Excel, including ANOVA
for identification of genes differentially expressed
amongst the groups (two or more groups) and t-test or F-
test (paired groups). The outputs are gene rank lists based
on statistical tests and figures based on visualization tools,
including heat map and Multi-Dimensional Scaling
which reduces high dimensional data to graphical dis-
plays. We have successfully applied BRB-Array Tools for
our Pathway Array data analysis (see next section).
Significance Analysis of Microarrays (SAM) is a super-
vised learning software for genomic array data mining
http://www-stat.stanford.edu/~tibs/SAM/. SAM is a statis-
tical tool for identifying significant genes in a set of
expression microarray experiments. It can also be applied
to data from Oligo or cDNA arrays, SNP arrays, protein
arrays, etc (Figure 6A) [25]. SAM correlates expression
data to clinical parameters including treatment, diagnosis
categories, survival time, paired (before and after), quan-
titative (e.g. tumor volume) and one-class. Both paramet-
ric and non-parametric tests can be performed by SAM.
SAM can perform the automatic imputation of missing
data via nearest neighbor algorithm. The adjustable
threshold determines the number of genes called signifi-
cant. SAM uses data permutations to provide an estimate
of FDR for multiple testing. The output of gene lists in
Excel workbook form can easily be exported into
TreeView, Cluster or other software. Finally, the genes are
web-linked to the Stanford SOURCE database.
Prediction Analysis of Microarrays (PAM) is a statistical
technique for class prediction and survival analysis from
gene expression data using nearest shrunken centroids
http://www-stat.stanford.edu/~tibs/PAM/ (Figure 6B).
The method of nearest shrunken centroids identifies sub-
sets of genes that best characterizes each class [26]. The
technique is general and can be used in many other clas-
sification problems. For survival outcomes, PAM uses pre-
diction by the 'supervised principal components' method.
PAM incorporates reliable statistical methods designed to
better manage the FDR. PAM estimates prediction error
via cross-validation and provides a list of significant genes
whose expression characterizes each diagnostic class. The
data from cDNA and oligo microarrays, protein expres-
sion data and SNP chip data can used for PAM analysis.Cell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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Signaling network construction
Although computational modeling platforms will soon
become standard tools in constructing signaling networks
for clinical applications, comprehensive tools are still not
presently available. To establish 2-dimensional or even 3
-dimensional signal signaling networks in cancer cells
requires the integration of mathematical, computational,
biology and clinical sciences. The data available from
genomic, proteomic and biochemical experiments creates
a framework for signaling network construction. Further-
more, the integration of data from of other genomic stud-
ies included mRNA expression, SNP, CNV, methylation
etc. is necessary to establish a comprehensive signaling
network.
The network construction is conceptually straightforward:
nodes represent proteins or genes and hubs represent the
central regulators that control other nodes through the
links which connects between node-node, node-hub, and
hub-hub (Figure 7). The most common mathematic mod-
eling tool is Bayesian network analysis [27]. A Bayesian
network is a probabilistic model that consists of two parts:
a dependency structure and local probability models. The
dependency structure specifies how the variables are
related to each other by drawing directed edges between
the variables without creating directed cycles. Each varia-
ble depends on a possibly empty set of other variables,
termed the "parents." The local probability model speci-
fies how the variables depend on the parents.
Statistical analysis of Pathway Array results Figure 6
Statistical analysis of Pathway Array results. A. SAM output of breast cancer data which showed a FDR 3.85% in 18 dif-
ferently expressed proteins between tumor and benign tissues. B. PAM output of Cross-validated probabilities of 9 differently 
expressed biomarkers between lung cancer (T) and normal tissues (N).
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Several computer programs are available for simple pre-
diction of signaling network and graphic presentation.
Weighted Co-expression Analysis is used to explore
molecular interaction networks across RNA expression in
different samples in microarray datasets [28]. In this
model, the network construction is based on the concept
that nodes represent genes and nodes are connected if the
corresponding genes are significantly co-expressed across
appropriately chosen tissue samples. The co-expression
networks can be organized into modules of system level
functionality for coordinated gene expression. Category
analysis and Gene set enrichment analysis (GSEA) pro-
vide pathway enrichment tools to help interpret datasets
[29]. This approach designed to detect the categories, or
sets, of genes where there are potentially small but coordi-
nated changes in the expression of groups of functionally
related genes. Ingenuity Pathway Analysis, a commercial
software, provides a link to database derived from litera-
ture to find function and pathways for microarray analysis
http://www.ingenuity.com/products/
pathways_analysis.html. Ingenuity Pathway Analysis is an
web-based application that enables users to analyze, inte-
grate, and understand data derived from gene expression,
microRNA, SNP and proteomic microarray [30]. The
capabilities of Ingenuity Pathway Analysis are to: 1) rank
the genes and proteins in a dataset according to the char-
acteristics that make a gene product a biologically plausi-
ble candidate biomarker; 2) measure whether a particular
gene or protein is detectable in sentinel tissues (e.g.,
blood, bone marrow), urine and other bodily fluids; 3)
select parameters that are most relevant to a biomarker
discovery project; 4) elucidate mechanisms linking poten-
tial markers to the disease or biological process of interest;
and 5) generate a list of candidate markers unique to one
treatment or disease, or common across all treatments.
Schematic representation of the signaling network of differentially expressed proteins Figure 7
Schematic representation of the signaling network of differentially expressed proteins. The figure was created 
using Ingeniuty and shows the connectivity between nodes (i.e. TCP1 and CDC42) and hubs (i.e. CCNB1, CTNNB1 and 
RELA). Solid lines indicate direct interaction. Dashed lines indicate indirect interaction. Arrows indicate stimulation. Bars indi-
cate inhibition.Cell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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Some existing signaling network databases are also avail-
able including KEGG pathway http://www.genome.jp/
kegg/pathway.html and BioCarta pathways http://
www.biocarta.com/genes/allpathways.asp. These net-
works were constructed based on published literature and
databases, such as Entrez Gene http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db_gene and
Gene Ontology, which provide molecular function, bio-
logical process and cellular location. Gene Ontology is a
major bioinformatics initiative that aims to standardize
the representation of gene and gene product attributes
across species and databases http://www.geneontol
ogy.org/GO.tools.shtml. The project provides a controlled
vocabulary of terms for describing gene product character-
istics and gene product annotation data from GO Consor-
tium members, as well as tools to access and process this
data.
Research and Clinical Applications for Pathway Array
The Pathway Array has broad applications in translational
research and clinical utilities, including discovering diag-
nostic and prognostic biomarkers, identifying novel ther-
apeutic targets, and providing tools for future
personalized therapy. The following are examples of Path-
way Array applications in different cancers.
Discovery of diagnostic biomarkers
Breast cancer is the second leading cancer death in
women. Breast cancer research in the past decade has
advanced our understanding of breast cancer biology and
improved diagnosis and treatment. Most advancement
has occurred from studies of breast cancer using tech-
niques such as, cytogenetics, gene expression array, SNP
array, copy number variation, DNA methylation, etc. We
recently completed a comparative study of 39 breast can-
cer patients that examined the differences in expression
pattern of invasive ductal carcinoma and the surrounding
normal tissues. The Pathway Array data was analyzed
using BRB-Array Tools and SAM as described above. Of
160 proteins/phospho-proteins tested (see Additional file
3, for a partial list of the antibodies), 56 are differentially
expressed with statistical significance (p < 0.05), including
but not limited to: Twist, Fas, PCNA, PTEN and cyclin B1.
Some proteins are only overexpressed in tumors (i.e.
PTEN), while others are down-regulated in tumor tissues
(i.e. cyclin B1). We further analyzed the expression data
using PAM and identified 12 proteins that best character-
ize tumor and normal class of breast tissues. Using these
proteins, the tumor and normal tissue was distinguished
with 96% accuracy in 24 pairs of breast cancer and normal
tissue specimens (Figure 8).
We further tested to see if selected signaling proteins can
separate breast cancer from other cancers, such as lung
cancer, since histologically distinguishing breast cancer
from other types of cancers may be a diagnostic challenge
in certain circumstances. Our results showed that using 13
differentially expressed proteins between breast cancer
and lung cancer, we were able to separate breast cancer
from lung cancer with 91% accuracy (Figure 9). These
results suggested that breast cancer and lung cancer have
distinct dysregulation and activation patterns, probably
due to the different mechanisms of carcinogenesis.
Discovery of prognostic biomarkers
Most studies that predict non-small cell lung cancer sur-
vival used a genomic microarray platform. For example,
Chen et al showed that 16 genes from an initial microarray
study and risk score analysis correlated with survival
among patients with NSLC [31]. The authors subse-
quently selected five genes (DUSP6, MMD, STAT1,
ERBB3, and LCK) for RT-PCR and decision-tree analysis.
The five-gene signature was an independent predictor of
relapse-free and overall survival. Fan et al. showed that a
13 gene profile associated with the vascular endothelial
growth factor (VEGF) subnetwork, including VEGF,
ANGPTL4, ADM and the monocarboxylic acid transporter
SLC16A3, can predict distant metastasis and poor out-
comes [32]. These results suggest that activation of certain
signaling network may correlate with a poor prognosis.
We recently analyzed the expression of p-CREB in lung
cancer using Pathway Array technique and found that it
differentially expressed in 56.4% of NSCLC compared
with surrounding normal tissue in our cohort of 39
patients. We further tested the expression of p-CREB in a
NSCLC tissue microarray (n = 91) using immunohisto-
chemical staining method and the expression pattern was
correlated with survival (Figure 10A and 10B). Our results
showed that p-CREB was expressed in the nucleus in 63%
of NSCLC and the increased expression of p-CREB corre-
lated with a good prognosis (Figure 10C and 10D).
Discovery of potential therapeutic targets
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the third leading cause of cancer
death in the world, with the five-year survival rate
approaching 7% [33]. Treatments of HCC include surgical
resection and transplantation, ablation and transarterial
chemoembolization, and systemic chemotherapy [34,35].
However, except for surgical resection/transplantation of
early stage HCC, the survival time is not significantly pro-
longed by any of these treatments. Therefore, develop-
ment of newer therapeutic targets for HCC treatment is
urgently needed.
We studied 10 tumor tissues and paired non-tumor tissues
from 10 hepatitis-related HCC patients. Among the 44
antibodies tested, 23 proteins and phosphoproteins were
detected and 22 had a more than 2-fold change betweenCell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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the cancerous and normal tissues. Of these proteins, XIAP
and CDK6 were highly expressed in tumors as compared
with surrounding tissues (54% and 46% tumors, respec-
tively). XIAP is a member of the IAP family (inhibitor of
apoptosis), which inhibits a subset of caspases (i.e. cas-
pase 3 and 9). CDK6 activates cyclin D1 and the cyclin
D1/CDK6 complex activates pRB and E2F which controls
the cell cycle progression from the mid-G1 to S phase.
Therefore, increased expression of XIAP and CDK6 in
HCC may result in decreased apoptosis and increased cell
proliferation.
In order to determine if XIAP and CDK6 can be therapeu-
tic targets, we applied siRNA technology to silence the
expression of XIAP and CDK6 in HCC cells. Our results
showed a significant reduction in cell viability by both
XIAP and CDK6 specific siRNAs and the cause of cell
death was necrosis (i.e. PI positive cells) rather than apop-
tosis (Annexin positive cells) (see Additional file 4). These
results indicate that both XIAP and CDK6 are important
for HCC cell survival. We further tested that small mole-
cules specific for these targets, including embolin for XIAP
and flavopiridol for CDKs. Both molecules showed a sig-
nificant inhibition of HCC cell growth, suggesting that
both XIAP and CDK6 can be potential targets for HCC
treatment.
Detection of signaling activities for personalized therapy
Currently, the treatment of most cancers is based on the
tissue types and clinical stages. This approach is often inef-
fective due to the heterogeneity of the tumors. Recently,
the use the signaling network approach to break down
complex oncogenic signaling networks into basic units, or
modules, of signaling activity (e.g., a protein phosphor-
ylating another protein to activate its kinase activity) and
demonstrate that gene expression signatures based on
these modules can predict the effectiveness of pathway-
specific therapeutics [36].
As stated above that current systemic chemotherapy for
HCC is ineffective [34,35]. A recent study showed that tar-
geted therapy with molecules, such as sorafenib which
inhibits multiple tyrosine kinase receptors (RAS/VEGFR)
[37], may offer some benefit with this deadly disease (~3
months improvement of survival). A reason for the lim-
ited benefit of signal pathway based treatment is the
redundancy and compensation of the signaling network
in HCC. Our recent study showed inhibition of XIAP and
Classifying benign (N) and malignant (T) breast tissues using 12 signaling-related proteins Figure 8
Classifying benign (N) and malignant (T) breast tissues using 12 signaling-related proteins. Based on the expres-
sion pattern, the tumors (left) were separated from the benign tissues (right) with only 1 benign (N8) and one tumor (T17) 
misclassified. Red: increased expression. Green: decreased expression. Black: no change. Gray: no expression.Cell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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CDK6 reduced HCC cell proliferation. However, a signifi-
cant reorganization of the signaling network observed,
including down regulation of tumor suppressors (p-p53
and CHK1 when XIAP silenced or p-RB when CDK6
silenced) and upregulation of tumor promoting proteins
(ETS1 when XIAP silenced or p-CREB when CDK6
silenced), which may confer the growth benefit for cancer
cells. Therefore, it is conceivable that inhibition of a main
pathway and an associated compensatory pathways, the
efficacy of chemotherapy will be significantly improved.
Another potential cause of treatment failure is the pheno-
typical heterogeneity of HCC that results from heteroge-
neous activation of cancer signaling network [38]. Our
study showed a significant variation in signaling transduc-
tion protein expression in different patients (see Addi-
tional file 5). For example, CDK6 was only expressed in
patient A while ERK1/2 was expressed in patient B and C.
In this case, if flavopiridal (a pan-CDK inhibitor) is used
to treat these patients, the drug may not have been effec-
tive in patients B, C and D. On the other hand, when sor-
afenib (a RAS/ERK pathway inhibitor) is used, the drug
may not have been effective for patient A and D. There-
fore, assessing the signaling pathway/network before
beginning treatment to identify patients that may benefit
from targeted therapies may improve the response rate.
Conclusion
Cancer is a complex disease that results from dysregula-
tion of signaling networks caused by the genetic and epi-
genetic alterations in cells. Therefore, determining the
underlying signaling network changes in cancer not only
help to understand the molecular mechanism of carcino-
genesis but also to identify the signature of signaling net-
works characteristic for specific cancer types that can be
used for diagnosis, prognosis and guidance for targeted
therapy. The scientific community will see a significant
advancement in cancer signaling network field in the next
5-10 years. Pathologists and laboratory scientists are in
the unique position to translate their knowledge of cancer
signaling network biology into relevant clinical practice.
Conceivably, "-omics" tools, such as DNA and protein
microarray, can be successfully used as tissue-based diag-
nostic and prognostic tools in the future. One ideal model
is that cancer patients may visit the oncologist,
cytopathologist or radiologist to perform a fine needle
aspiration biopsy (FNA) of the tumor. Then, the FNA
materials are examined by a cytopathologist for tumor
cells and analyzed by a molecular pathologist to recon-
struct the signaling network using "-omics tools." This
information would be integrated so that the oncologist
can use the signaling network information, in addition to
clinical and pathological data, to determine the prognosis
and customize the treatment (i.e. personalized therapy).
Classify lung cancer (L) and breast cancer (B) using 13 signaling proteins (30 lung cancer samples and 34 breast cancer samples) Figure 9
Classify lung cancer (L) and breast cancer (B) using 13 signaling proteins (30 lung cancer samples and 34 breast 
cancer samples). Based on the expression pattern, the lung cancers (left) were separated from the breast cancers (right) 
with 3 breast cancers and 3 lung cancers misclassified. Red: increased expression. Green: decreased expression. Black: no 
change. Gray: no expression.Cell Division 2009, 4:20 http://www.celldiv.com/content/4/1/20
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Prognostic value of phosphorylated CREB (p-CREB) for lung cancer Figure 10
Prognostic value of phosphorylated CREB (p-CREB) for lung cancer. A and B. Immunochemistry staining of p-CREB 
on a lung cancer tissue microarray (A: 10× magnification; B: 400× magnification). Positive stains (brown) of p-CREB were seen 
in tumor cell nuclei. C and D. Survival analysis using p-CREB (C) and total CREB (D) expression. The results showed that p-
CREB expression correlated better survival. In contrary, expression of unphosphorylated CREB had not prognostic value.
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